• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Therapeutic Areas
  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS opens Phenotypic Screening Center

Largest organ-on-a-chip screen on a 3D angiogenesis assay

 

Leiden, May 27, 2021 – MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate® technology offers the scalability and the throughput needed for drug discovery studies.

“We are very proud to open up this new center,” said Jos Joore, CEO of MIMETAS. “Our new Phenotypic Screening Center facilitates high-throughput organ-on-a-chip screening combined with high-content imaging and machine learning data analysis to identify drug candidates for today’s unmet medical needs. Our customers understand that human-relevant disease models should be at the basis of every drug discovery effort. Moreover, these cutting-edge technologies stimulate the creativity and purpose of our scientists to make a difference in the lives of patients.”

Largest Organ-on-a-Chip compound screen

MIMETAS recently reported a successful 1,546 compound screen in duplicate on a 3D angiogenesis assay in the OrganoPlate® 3-lane 64. Promising hit compounds from this screen are currently under investigation. “To our knowledge, this is the largest organ-on-a-chip screen ever reported,” explained Joore. “We partner with large pharmaceutical companies, that need our disease model screening expertise, and can bring promising candidates to the clinic fast. In this way, we make sure that we bring novel drugs to patients in the most efficient manner.”

New energy-neutral laboratory

The brand-new screening center is located in the new head office of MIMETAS at the shore of the Old Rhine, the ancient northern border of the Roman Empire. It is the first energy-neutral laboratory building in the Netherlands. This sustainable building has accomplished a 40% carbon dioxide reduction by reusing materials from a former Leiden University complex. Joore adds: “It is highly inspiring to perform our research surrounded by materials recycled from labs where Nobel-prize winners have done their groundbreaking science.”


Go to the official press release Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all